Ricevi le ultime notizie sulle azioni PDS Biotechnology con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di PDSB

Ultime notizie per

PDS BIOTECHNOLOGY CORP

PDS Biotechnology

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology Corp

News

Health Care

Press Releases

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

Earnings

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Small Cap

Opinion

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

IOBT

OLMA

ONCY

PDSB

PRPH

TSX:ONC

Annovis Bio

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Celularity

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Cue Biopharma

Dyadic International, Inc. - Common Stock

Dyadic International

Equillium

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroGen

Generation Bio

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

Lantern Pharma

LAVA Therapeutics

Medicus Pharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

RenovoRx

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Xilio Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

Comments

PDS Biotechnology Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO